

			Heterozygote	1.68 x 10 <sup>-4</sup>
				0.32 (0.088-1.16)
			Homozygote	0.089
				2.88 (1.65-5.05)
rs9599819	DACH1	13q21	Allele	0.61
				1.11 (0.75-1.65)
			Genotype	5.08 x 10 <sup>-6</sup>
			Heterozygote	5.77 x 10 <sup>-4</sup>
				1.73 (1.06-2.81)
			Homozygote	0.034
rs3763022	SH2TC2	5q33	Allele	2.18 x 10 <sup>-6</sup>
				6.44 (2.53-16.36)
			Genotype	1.78 x 10 <sup>-5</sup>
			Heterozygote	0.17

			Homozygote	5.59 x 10 <sup>-6</sup>
				6.62 (2.54-17.22)
rs12595534	TRPM1	15q13	Allele	4.26 x 10 <sup>-5</sup>
				2.13 (1.48-3.08)
			Genotype	1.10 x 10 <sup>-5</sup>
			Heterozygote	0.011
				8.91 (2.69-29.52)
			Homozygote	5.98 x 10 <sup>-6</sup>
				1.94 (1.19-3.16)
rs10510110	PLEKHA1	10q26	Allele	4.93 x 10 <sup>-6</sup>
				2.35 (1.62-3.43)
			Genotype	2.07 x 10 <sup>-5</sup>
			Heterozygote	9.50 x 10 <sup>-6</sup>
				2.92 (1.25-6.81)

---

Homozygote

0.014

3.09 (1.88-5.09)

---

Genome positions refer to the human March 2008 (build 36.3) assembly. *P* values

were calculated for three models (allele, genotype, heterozygote and

homozygote) using Fisher's exact test. OR, odds ratio; CI, confidence

interval. ORs and CIs were calculated using Woolf's method.

感覚器障害研究事業

緑内障の危険因子の解明による診断法の開発、緑内障マウスを用いた  
視神経保護薬の開発と予防・治療法への応用  
(H18 - 感覚器 - 一般 - 002)

平成 20 年度 総括研究報告書

主任研究者 岩田 岳

平成 21 年 3 月